- Home
- CTNM
CTNM
Contineum Therapeutics Inc. Class A Common Stock
as 04-01-2025 3:34pm EST
Stocks
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2024 |
| Target Price: | $24.80 | AVG Volume (30 days): | 52.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.92 - $22.00 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 108.33% |
Latest Contineum Therapeutics Inc. Class A Common Stock News
CTNM Breaking Stock News: Dive into CTNM Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Simply Wall St.
20 days ago
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%
Business Wire
21 days ago
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
Business Wire
a month ago
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
Business Wire
a month ago
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
Business Wire
a month ago
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
Business Wire
3 months ago
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
GlobeNewswire
3 months ago
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
Compare CTNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTNM Contineum Therapeutics Inc. Class A Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.